Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Avatar

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, and How to Salvage Therapy

By Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018) FEATURING Sundar Jagannath
October 2018
0 Comments
Login to view comments. Click here to Login

Featured Video

10:37
Amgen Oncology

Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse

Feat. J. Abbas

Featured Video

10:37
Amgen Oncology

Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse

Feat. J. Abbas

Related Content

AUTOPLAY
Moffitt Cancer Center

16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Sat, Jan 18, 2020
The University of Kansas Cancer Center

KU ASH 2019 Review: Current Updates in Hematologic Diseases

Sat, Jan 18, 2020
UChicago Medicine Comprehensive Cancer Center

UChicago Annual Updates from ASH 2019

Fri, Feb 28, 2020
Indy Hematology Review

17th Indy Hematology Review

Sat, Mar 21, 2020
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Fri, Feb 7, 2020
12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refra...

Feat. M. Dimopoulos
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
19:49
Gareth J Morgan

Contemporary Design of MM Treatment: Developing New Therapeutic Endpoint...

17:03
Ajai Chari

Diagnosing Smoldering Multiple Myeloma

05:05
Indy Hematology Review

Risk of Progression of Smoldering Myeloma to Active Multiple Myeloma

Feat. K. Anderson
10:17
Amgen Oncology

Multiple Myeloma: Use of Proteasome Inhibitor at First Relapse-A Case Study

Feat. H. Kaya
09:49
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

15:02
Krina Patel

Clinical Trials in Myeloma in 2018

15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

10:37
Amgen Oncology

Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse

Feat. J. Abbas
13:26
Shaji Kumar

Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma

17:17
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Emerging Data on Management and Imaging of Myeloma Bone Disease

Feat. M. Dimopoulos
17:03
Thomas Martin

Novel Clinical Trials for Smoldering Multiple Myeloma in 2018

16:22
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

FDA Approves Selinexor for Refractory Multiple Myeloma, STORM Study

Feat. S. Jagannath
21:40
Natalie Callander

Smoldering Myeloma: Risk Stratification and Therapeutic Options

12:32
Indy Hematology Review

What's New in Immunotherapy and Genomics in Multiple Myeloma?

Feat. K. Anderson
15:10
Krina Patel

Developing CAR T-cells in Multiple Myeloma